Search
Samsung Biologics to Spin Off Biosimilars Business for Enhanced Focus
2025-05-22 /
Read about 0 minute
Author：小编
Samsung Biologics, a subsidiary of the renowned South Korean conglomerate Samsung Group, unveiled its strategy on Thursday to spin off its biosimilars development business. This strategic move aims to streamline operations and intensify its commitment to its core Contract Development and Manufacturing Organization (CDMO) services. Consequently, the company will establish a new entity named Samsung Epis Holdings, under which Samsung Bioepis Co., the biosimilars developer, will operate as a wholly-owned subsidiary. The primary objective of this reorganization is to consolidate resources on the CDMO business, thereby bolstering Samsung Biologics' competitive edge in the market.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
